P. B. Chapman, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011.
DOI : 10.1056/NEJMoa1103782

V. Huang and M. Anadkat, Dermatologic manifestations of cytotoxic therapy, Dermatologic Therapy, vol.139, issue.3, pp.401-410, 2011.
DOI : 10.1111/j.1529-8019.2011.01432.x

J. Lemieux, E. Maunsell, and L. Provencher, Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review, Psycho-Oncology, vol.15, issue.4, pp.317-328, 2008.
DOI : 10.1002/pon.1245

S. M. Flory, Onycholysis Associated with Weekly Administration of Paclitaxel, Annals of Pharmacotherapy, vol.86, issue.5, pp.584-586, 1999.
DOI : 10.1007/BF00192885

M. Mizumoto, Frequency and characteristics of docetaxel-induced radiation recall phenomenon, International Journal of Radiation Oncology*Biology*Physics, vol.66, issue.4, pp.1187-1191, 2006.
DOI : 10.1016/j.ijrobp.2006.05.073

J. Burdon, R. Bell, J. Sullivan, and M. Henderson, Adriamycin-induced recall phenomenon 15 years after radiotherapy, JAMA: The Journal of the American Medical Association, vol.239, issue.10, p.931, 1978.
DOI : 10.1001/jama.239.10.931b

A. D. Lipworth, C. Robert, and A. Zhu, Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib, Oncology, vol.77, issue.5, pp.257-271, 2009.
DOI : 10.1159/000258880

M. W. Saif, Capecitabine and hand???foot syndrome, Expert Opinion on Drug Safety, vol.13, issue.12, pp.159-169, 2011.
DOI : 10.1093/annonc/mdp047

C. Bachmeyer and S. Aractingi, Neutrophilic eccrine hidradenitis, Clinics in Dermatology, vol.18, issue.3, pp.319-330, 2000.
DOI : 10.1016/S0738-081X(99)00123-6

C. Bachmeyer, P. Chaibi, and S. Aractingi, Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor, British Journal of Dermatology, vol.5, issue.2, pp.354-355, 1998.
DOI : 10.1001/archderm.130.1.77

J. L. Bolognia, D. L. Cooper, and E. J. Glusac, Toxic erythema of chemotherapy: A useful clinical term, Journal of the American Academy of Dermatology, vol.59, issue.3, pp.524-529, 2008.
DOI : 10.1016/j.jaad.2008.05.018

D. Marcoux, R. Anex, and P. Russo, Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine, Journal of the American Academy of Dermatology, vol.43, issue.3, pp.540-546, 2000.
DOI : 10.1067/mjd.2000.106239

K. Chittari, S. Tagboto, and B. B. Tan, Cyclophosphamide-induced nail discoloration and skin hyperpigmentation: a rare presentation, Clinical and Experimental Dermatology, vol.60, issue.3, pp.405-406, 2009.
DOI : 10.1111/j.1365-2230.2008.02896.x

M. E. Teresi, D. J. Murry, and A. S. Cornelius, Ifosfamide-induced hyperpigmentation, Cancer, vol.47, issue.9, pp.2873-2875, 1993.
DOI : 10.1002/1097-0142(19930501)71:9<2873::AID-CNCR2820710931>3.0.CO;2-6

K. L. Goldfeder, Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.494-499, 2007.
DOI : 10.1016/j.jaad.2006.11.009

W. Weger, B. Kränke, A. Gerger, W. Salmhofer, and E. Aberer, Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine, Journal of the American Academy of Dermatology, vol.59, issue.2, pp.4-6, 2008.
DOI : 10.1016/j.jaad.2007.06.040

A. Abess, D. M. Keel, and B. S. Graham, Flagellate Hyperpigmentation Following Intralesional Bleomycin Treatment of Verruca Plantaris, Archives of Dermatology, vol.139, issue.3, pp.337-339, 2003.
DOI : 10.1001/archderm.139.3.337

J. C. English, R. Toney, and J. W. Patterson, Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin, Journal of Cutaneous Pathology, vol.56, issue.6, pp.591-595, 2003.
DOI : 10.1006/jmcc.1996.0186

M. Deslandres, V. Sibaud, C. Chevreau, and J. P. Delord, Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors], Ann Dermatol Venereol Spec No, vol.1, pp.16-24, 2008.

S. Schubbert, K. Shannon, and G. Bollag, Hyperactive Ras in developmental disorders and cancer, Nature Reviews Cancer, vol.91, issue.4, pp.295-308, 2007.
DOI : 10.1038/nrc2109

C. Robert, Cutaneous side-effects of kinase inhibitors and blocking antibodies, The Lancet Oncology, vol.6, issue.7, pp.491-500, 2005.
DOI : 10.1016/S1470-2045(05)70243-6

J. C. Hu, P. Sadeghi, L. C. Pinter-brown, S. Yashar, and M. W. Chiu, Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management, Journal of the American Academy of Dermatology, vol.56, issue.2, pp.317-326, 2007.
DOI : 10.1016/j.jaad.2006.09.005

C. Robert, C. Mateus, A. Spatz, J. Wechsler, and B. Escudier, Dermatologic symptoms associated with the multikinase inhibitor sorafenib, Journal of the American Academy of Dermatology, vol.60, issue.2, pp.299-305, 2009.
DOI : 10.1016/j.jaad.2008.06.034

V. Sibaud, I. Garrido-stowhas, E. Cottura, and C. Chevreau, Effets indésirables dermatologiques des thérapies ciblées antiangiogéniques, Bull Cancer, vol.98, pp.1221-1229, 2011.

I. Manousardis, S. Mavridou, S. Goerdt, M. Leverkus, and J. , Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management, Journal of the European Academy of Dermatology and Venereology, vol.26, issue.Suppl. 5, pp.11-18, 2013.
DOI : 10.1111/j.1468-3083.2012.04546.x

P. L. Mattei, Cutaneous effects of BRAF inhibitor therapy: a case series, Annals of Oncology, vol.24, issue.2, pp.530-537, 2013.
DOI : 10.1093/annonc/mds292

S. Adachi, T. Yoshimura, T. Matsuoka, K. Okada, T. Yasuda et al., Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapyGan To Kagaku Ryoho, pp.1453-1459, 2011.

L. Fox, Nail toxicity associated with epidermal growth??factor receptor inhibitor therapy, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.460-465, 2007.
DOI : 10.1016/j.jaad.2006.09.013

E. Cowen, Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.514-521, 2007.
DOI : 10.1016/j.jaad.2006.11.004

J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert, Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor, Archives of Dermatology, vol.144, issue.7, pp.886-892, 2008.
DOI : 10.1001/archderm.144.7.886

R. Anforth, T. Blumetti, R. Kefford, R. Sharma, R. Scolyer et al., Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma, British Journal of Dermatology, vol.230, issue.Suppl., 2012.
DOI : 10.1111/j.1365-2133.2012.11155.x

A. Sekulic, M. Migden, A. Oro, L. Dirix, K. Lewis et al., Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma, New England Journal of Medicine, vol.366, issue.23, pp.2171-2180, 2012.
DOI : 10.1056/NEJMoa1113713

J. Arnault, J. Wechsler, and B. Escudier, Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib, Journal of Clinical Oncology, vol.27, issue.23, pp.59-61, 2009.
DOI : 10.1200/JCO.2009.23.4823

J. Sosman, K. Kim, L. Schuchter, R. Gonzalez, A. Pavlick et al., Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, 2012.
DOI : 10.1056/NEJMoa1112302

P. Mattei, M. Alora-palli, S. Kraft, D. Lawrence, K. Flaherty et al., Cutaneous effects of BRAF inhibitor therapy: a case series, Annals of Oncology, vol.24, issue.2, pp.530-537, 2013.
DOI : 10.1093/annonc/mds292

E. Rodríguez-murphy, S. Villanueva-herraiz, M. Ortega-garcía, A. Pérez-feliu, L. Soria et al., Camps-Herrero C Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].Farm Hosp, pp.114-134, 2011.

C. Robert, C. Mateus, A. Spatz, J. Wechsler, and B. Escudier, Dermatologic symptoms associated with the multikinase inhibitor sorafenib, Journal of the American Academy of Dermatology, vol.60, issue.2, pp.299-305, 2009.
DOI : 10.1016/j.jaad.2008.06.034

L. Boussemart, Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Annals of Oncology, vol.24, issue.6, pp.1691-1697, 2013.
DOI : 10.1093/annonc/mdt015

S. Adachi, Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapy], Gan To Kagaku Ryoho, vol.38, pp.1453-1456, 2011.

C. Voilliot-trotot, Effets ind??sirables cutan??s et retentissement sur la qualit?? de vie des inhibiteurs de mTOR au cours du traitement du cancer du rein, Annales de Dermatologie et de V??n??r??ologie, vol.140, issue.5, pp.353-362, 2013.
DOI : 10.1016/j.annder.2013.02.023

M. Augustin, K. Krüger, M. A. Radtke, I. Schwippl, and K. Reich, Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany, Dermatology, vol.216, issue.4, pp.366-372, 2008.
DOI : 10.1159/000119415

S. Joe, M. E. Woolley, G. K. Brown, M. Ghahramanlou-holloway, and A. Beck, Psychometric Properties of the Beck Depression Inventory???II in Low-Income, African American Suicide Attempters, Journal of Personality Assessment, vol.44, issue.5, pp.521-523, 2008.
DOI : 10.1037/1040-3590.7.4.472

A. Vultur, J. Villanueva, and M. Herlyn, BRAF Inhibitor Unveils Its Potential against Advanced Melanoma, Cancer Cell, vol.18, issue.4, pp.301-302, 2010.
DOI : 10.1016/j.ccr.2010.10.001

URL : http://doi.org/10.1016/j.ccr.2010.10.001

R. Anforth, P. Fernandez-peñas, and G. Long, Cutaneous toxicities of RAF inhibitors, The Lancet Oncology, vol.14, issue.1, pp.11-18, 2013.
DOI : 10.1016/S1470-2045(12)70413-8

H. Tomková, Cetuximab-induced cutaneous toxicity, Journal of the European Academy of Dermatology and Venereology, vol.13, issue.suppl 2, pp.692-696, 2010.
DOI : 10.1111/j.1468-3083.2009.03490.x

S. Segaert and E. Van-cutsem, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors, Annals of Oncology, vol.16, issue.9, pp.1425-1433, 2005.
DOI : 10.1093/annonc/mdi279

E. W. Cowen, Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.514-517, 2007.
DOI : 10.1016/j.jaad.2006.11.004

E. G. Grevelman and W. P. Breed, Prevention of chemotherapy-induced hair loss by scalp cooling, Annals of Oncology, vol.16, issue.3, pp.352-358, 2005.
DOI : 10.1093/annonc/mdi088

P. Gilbar, A. Hain, and V. Peereboom, Nail Toxicity Induced by Cancer Chemotherapy, Journal of Oncology Pharmacy Practice, vol.112, issue.3, pp.143-155, 2009.
DOI : 10.1177/1078155208100450

H. Son, W. Y. Lee, W. Lee, S. H. Yun, and H. Chun, Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy, Yonsei Medical Journal, vol.50, issue.6, pp.796-802, 2009.
DOI : 10.3349/ymj.2009.50.6.796

E. Y. Chu, Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study, Journal of the American Academy of Dermatology, vol.67, issue.6, pp.1265-1272, 2012.
DOI : 10.1016/j.jaad.2012.04.008

P. A. Ascierto, Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, issue.26, pp.3205-3211, 2013.
DOI : 10.1200/JCO.2013.49.8691

M. E. Lacouture, Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma, The Oncologist, vol.18, issue.3, pp.314-322, 2013.
DOI : 10.1634/theoncologist.2012-0333

C. Robert, J. Arnault, and C. Mateus, RAF inhibition and induction of cutaneous squamous cell carcinoma, Current Opinion in Oncology, vol.23, issue.2, pp.177-182, 2011.
DOI : 10.1097/CCO.0b013e3283436e8c

F. Su, Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors, New England Journal of Medicine, vol.366, issue.3, pp.207-215, 2012.
DOI : 10.1056/NEJMoa1105358

G. Hatzivassiliou, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, vol.50, issue.7287, pp.431-435, 2010.
DOI : 10.1038/nature08833

O. Forslund, H. Ly, C. Reid, and G. Higgins, A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis, British Journal of Dermatology, vol.80, issue.1, pp.64-73, 2003.
DOI : 10.1046/j.1365-2133.1999.02972.x

S. Majewski and S. Jablonska, Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion, Cancer Res, vol.57, pp.4214-4216, 1997.

M. Holderfield, Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors, Cancer Research, vol.74, issue.8, 2014.
DOI : 10.1158/0008-5472.CAN-13-1065-T

I. Manousaridis, S. Mavridou, S. Goerdt, M. Leverkus, and J. Utikal, Cutaneous side effects of inhibitors of the RAS, ERK signalling pathway and their management

P. R. Cohen, A. Y. Bedikian, and K. B. Kim, Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib, J Clin Aesthet Dermatol, vol.6, pp.27-37, 2013.

H. A. Haenssle, Dynamic Changes in Nevi of a Patient With Melanoma Treated With Vemurafenib, Archives of Dermatology, vol.148, issue.10, pp.1183-1185, 2012.
DOI : 10.1001/archdermatol.2012.2649

M. Bennani-lahlou, N??vus ??ruptifs sous soraf??nib, Annales de Dermatologie et de V??n??r??ologie, vol.135, issue.10, pp.672-674, 2008.
DOI : 10.1016/j.annder.2008.04.016

L. Zimmer, Inhibition, Journal of Clinical Oncology, vol.30, issue.19, pp.2375-2383, 2012.
DOI : 10.1200/JCO.2011.41.1660

N. Dhomen, Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice, Cancer Cell, vol.15, issue.4, pp.294-303, 2009.
DOI : 10.1016/j.ccr.2009.02.022

S. Debarbieux, Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy, British Journal of Dermatology, vol.27, issue.6, pp.1230-1235, 2013.
DOI : 10.1111/bjd.12210

S. Dalle, N. Poulalhon, and L. Thomas, Vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med, vol.365, pp.1448-1449, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00790751

P. Gelot, Vemurafenib: an unusual UVA-induced photosensitivity, Experimental Dermatology, vol.26, issue.4, pp.297-298, 2013.
DOI : 10.1111/exd.12119

K. Young, A. Minchom, and J. Larkin, mutation, Future Oncology, vol.8, issue.5, pp.499-507, 2012.
DOI : 10.2217/fon.12.43

R. Dummer, J. Rinderknecht, and S. M. Goldinger, Ultraviolet A and Photosensitivity during Vemurafenib Therapy, New England Journal of Medicine, vol.366, issue.5, pp.480-481, 2012.
DOI : 10.1056/NEJMc1113752

A. C. Rosen, Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic, American Journal of Clinical Dermatology, vol.46, issue.13, pp.327-333, 2013.
DOI : 10.1007/s40257-013-0021-0

A. Osio, Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors, British Journal of Dermatology, vol.25, issue.3, pp.515-521, 2009.
DOI : 10.1111/j.1365-2133.2009.09214.x

V. Sibaud, HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand-Foot Syndrome, The Oncologist, vol.16, issue.10, pp.1469-1478, 2011.
DOI : 10.1634/theoncologist.2011-0033

E. Basch, Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study, The Lancet Oncology, vol.7, issue.11, pp.903-909, 2006.
DOI : 10.1016/S1470-2045(06)70910-X